U.S. Oncology seeks $100 million term loan add-on

By Sara Rosenberg

New York, June 15 - U.S. Oncology Inc. is currently in market with a $100 million add-on (Ba3/B+) to its term loan that will be used to reduce revolver outstanding amounts, according to a market source.

The add-on was launched earlier this week with pricing of Libor plus 225 basis points, in-line with existing term loan pricing, the source said.

JPMorgan is leading the deal.

U.S. Oncology is a Houston-based cancer-care services company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.